Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEM/RZR DDI with Digoxin and Rosuvastatin
NCT06921941Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemnifosbuvir + ruzasvir in hepatitis C (HCV) (2 cohorts), sponsored by Atea Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration (Cmax) of Digoxin and Rosuvastatin at Day 29 and Area Under the Curve (AUC) of Digoxin and Rosuvastatin at Day 29. Started Apr 2025; status: completed.
02
Drugs
bemnifosbuvir + ruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT06921941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06921941.